Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer

Key facts

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Principal Investigator

Axel Bex

The Netherlands Cancer Institute

Intervention

timing of surgery(procedure)

Enrollment

99 enrolled

Eligibility

18-120 years · All sexes

Timeline

2010 – 2017

Study locations (29)

• Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
• Cliniques Universitaires St. Luc, Brussels, Belgium
• Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium
• Universitair Ziekenhuis Gent, Ghent, Belgium
• Virga Jesse Hospital, Hasselt, Belgium
• AZ Groeninghe - Campus Loofstraat, Kortrijk, Belgium
• AZ Damiaan - Campus Sint-Jozef, Ostend, Belgium
• Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
• CHUM - Pavillon Saint-Luc, Montreal, Quebec, Canada
• Montreal General Hospital, Montreal, Canada
• The Ottawa Hospital, The Integrated Cancer Program- General Campus, Ottawa, Canada
• University Health Network - Oci / Princess Margaret Hospital, Toronto, Canada
• Diamond Health Care Centre, Vancouver, Canada
• San Camillo Forlanini Hospitals, Roma, Italy
• Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
• +14 more locations on ClinicalTrials.gov

Collaborators

Wales Cancer Trials Unit · Canadian Urologic Oncology Group · Institute of Cancer Research, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →